Neoplasms

Digestive System Diseases

All Conditions

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Herbal and Botanical

All Drugs and Chemicals

Cola

Multivisceral resection for locally advanced colon cancer.

Multivisceral resection

The aim of the present study is to assess the post-operative outcomes (morbidity and mortality) in relation to preoperative data and the oncological outcomes (overall and disease-free survival) in patients with a locally advanced colon cancer (LACC) with the necessity of a multivisceral resection (MVR).

All patients that meet the inclusion criteria will be registered in a retrospective database from 2014 to 2019 (5 years) Data will be reported for every patients with colon cancer to have had either a resection of another organ or structure in addition to resection of the primary tumor, or to have had a T4 (a or b) tumour on postoperative histopathology.

Data included are patient demographics, ASA score, tumor localization, preoperative imaging, neoadjuvant treatments, type of bowel resection and adjacent organs resected, tecnique (laparoscopic/laparotomic), postoperative complications and 30-day mortality, histopathology data including TNM scoring, completeness of surgical procedure (R0 to R2) and infiltration of tumor cells in resected tissues, adjuvant oncological treatments, and long term follow-up data on local and distant recurrence and survival.

Surgery for Locally Advanced Colon Cancer: is it Worth it? A Multicenter Retrospective Analysis.

Surgery for Locally Advanced Colon Cancer: is it Worth it? A Multicenter Retrospective Analysis. (LACC Trial)

Data will retrospectively collected from a maintained database in each center, created by the. A local study manager will be identified for each participating center.

I evaluate peri and post-operative surgical (e.g. intraabdominal collection, fistula, anastomotic leak) and medical (e.g. pneumoniae, deep vein thrombosis) complications

I evaluate in-hospital and 30-day mortality correlate to the intervention

The length of time from the intervention that patients diagnosed with a T4 colon cancer are still alive.

The measure of time after treatment during which no sign of recurrence (local or metastatic) is found.

Santo Spirito Hospital, Italy

Dirigente Medico I livello Chirurgia Generale

Symptoms and General Pathology

Wounds and Injuries

Hyperthermia

Fever

Carcinoma

Peritoneal Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Abdominal Neoplasms

Peritoneal Diseases

Antineoplastic Agents

Mitomycins

Mitomycin

Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC

HIPEC with MMC: Mitomycin C (MMC) (30 mg/m2 of body surface area). Closed technique, as preferred. Duration: 60 minutes. Mean Intra-abdominal Temperature: 43°C.

Kefeng Ding, Prof.

Multicentric randomised trial. The goal of this clinical research study is to learn if hyperthermic intraperitoneal chemotherapy (HIPEC) will help to decrease the rate of peritoneal carcinomatosis(PC) in patients with high risk of developing PC of colorectal cancer. The safety of this treatment will also be studied.

Hyperthermic intraperitoneal chemotherapy(HIPEC) is a recently validated option for the treatment of peritoneal carcinomatosis from colorectal or ovarian origin. This therapeutic program demonstrated a significant improvement of overall survival of the disease. It is not yet known whether surgery followed by HIPEC is effective on decreasing the rate of peritoneal carcinomatosis(PC) in patients with high risk of developing PC of colorectal cancer.Patients with a high risk of developing colorectal Peritoneal Carcinomatosis (PC), defined by Colorectal Cancer With a Resected Minimal Synchronous PC or Ovarian Metastases, or identified T4 by intraoperative pathological diagnosis, or Tumour Rupture in the Abdominal Cavity. If patients with a high risk of developing PC identified by preoperative examination, they will be informed and will sign the consent. After complete resection of their tumor, they will be randomised to surveillance alone (control group) or HIPEC (experimental group). All patients will receive the current standard postoperative adjuvant treatment : 6 months of systemic chemotherapy (currently including FOLFOX4, mFOLFOX6, CapeOx or Capecitabine regimen which could be modified if the standard is modified). Then a work-up is done to find recurrence. If the recurrence occurs, the patient will be treated with the best known treatment.

Surgery With HIPEC in Treating Patients With a High Risk of Developing Colorectal Peritoneal Carcinomatosis

Randomized Multicentric Phase III Trial Comparing Simple Surgery to Surgery Plus HIPEC (Hyperthermic Intraperitoneal Chemotherapy) With MMC in Colorectal Patients Who Have a High Risk of Developing Colorectal Peritoneal Carcinomatosis

Toxicity induced by HIPEC using the NCI CTC criteria; one month and six months morbidity.

Subgroup analysis: pT4; pts. ≤ 40yrs.

Duration of operation; return of bowel function; length of hospital stay; return to normal activity; six months and one year QOL, using the SF-36 v1.0; percentage of patients in both arms completing the scheduled postoperative chemotherapy; Subgroup analysis: pT4; pts. ≤ 40yrs.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Surgery for Locally Advanced Colon Cancer: is it Worth it? A Multicenter Retrospective Analysis.	NCT04646772	Malignant Neopl...	Multivisceral r...	18 Years -	Santo Spirito Hospital, Italy
Surgery With HIPEC in Treating Patients With a High Risk of Developing Colorectal Peritoneal Carcinomatosis	NCT02179489	Malignant Neopl... Peritoneal Carc...	Surgery and Hyp...	18 Years - 75 Years	Zhejiang University
Surgery With HIPEC in Treating Patients With a High Risk of Developing Colorectal Peritoneal Carcinomatosis	NCT02179489	Malignant Neopl... Peritoneal Carc...	Surgery and Hyp...	18 Years - 75 Years	Zhejiang University
Surgery for Locally Advanced Colon Cancer: is it Worth it? A Multicenter Retrospective Analysis.	NCT04646772	Malignant Neopl...	Multivisceral r...	18 Years -	Santo Spirito Hospital, Italy

Spots Global Cancer Trial Database for malignant neoplasm of large intestine tnm staging primary tumor (t) t4